Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Smith Genetics Research LLC is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution activity is confined to 1 distinct examiner and 1 distinct art unit, indicating a narrow and specific focus for the company's current patent office interactions. The presence of only 1 pending office action suggests a limited volume of active applications requiring immediate response.
The busiest examiner for this portfolio is AULAKH, CHARANJIT, who is currently handling the 1 pending office action. As there is only 1 distinct examiner involved, the company's immediate prosecution success in the Biotechnology & Pharmaceuticals sector relies on the specific feedback from AULAKH, CHARANJIT. The use of 1 distinct art unit further concentrates the regulatory environment, as the company does not currently face multiple sets of art unit-specific guidelines.
With 1 pending office action assigned to 1 distinct examiner, the administrative burden is minimal but highly centralized. AULAKH, CHARANJIT, as the busiest examiner with 1 pending action, is the sole point of contact for the company's current pending matters. This profile, characterized by 1 distinct art unit and 1 pending office action, reflects a singular point of focus for Smith Genetics Research LLC during the current prosecution cycle.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AULAKH, CHARANJIT | 1 | 80.7% | -14.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18218645 | TREATMENT OF AUTONOMIC DYSFUNCTION RESULTING FROM OPIOID USE | AULAKH, CHARANJIT | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18218645 | TREATMENT OF AUTONOMIC DYSFUNCTION RESULTING FROM OPIOID USE | AULAKH, CHARANJIT | 1621 | §101§103§112DP | Non-Final OA | — | Pending | Jul 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSmith Genetics Research LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Charanjit Aulakh has the most, with 1 of Smith Genetics Research LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
